Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies

Launched by UNIVERSITY CHILDREN'S HOSPITAL, ZURICH · Aug 8, 2024

Keywords

ClinConnect Summary

The Drug Response Profiling (DRP) Registry Zurich for Hematological Malignancies is a study designed to explore how different treatments can work for patients with blood cancers, like leukemia, myeloma, and lymphoma. Researchers will take samples of cancer cells from patients and test how these cells respond to various drugs in a lab setting. By doing this, they hope to find personalized treatment options that are more effective for each individual, especially for those whose cancer has not responded to standard therapies.

To participate in this study, patients must be under 40 years old and have a diagnosis of a blood cancer, whether it's the first time they are diagnosed or if their cancer has returned or become resistant to treatment. Participants need to agree to allow their tumor samples to be used for research and provide informed consent. Those involved can expect their cancer cells to be tested to see which drugs might work best for them, helping their doctors make more informed decisions about treatment. The study is currently recruiting participants, and it aims to improve how we understand and treat these challenging diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Pediatric and adult patients below the age of 40 years
• • Diagnosis of hematological malignancy (primary, relapsed or refractory) including leukemia, myeloma or lymphoma
• • Tumor material collected as part of routine diagnostics and willingness to donate tumor material for translational research
• • Patient and/or guardian has signed the informed consent of the DRP registry or of a clinical trial which includes DRP as add-on research.
• Exclusion Criteria:
• • Missing informed consent for the registry or of a clinical trial which includes DRP as add-on research